PTK7: Exploring a Promising Target for Cancer Therapeutics

Protein tyrosine kinase 7 (PTK7) is an evolutionarily conserved transmembrane receptor belonging to the receptor tyrosine kinase (RTK) family. Also written as tyrosine kinase 7 (PTK7), it is a catalytically inactive pseudokinase rather than an active kinase enzyme.

PTK7 was initially discovered due to its upregulated gene expression in colon cancer cells; hence, it is also known as colon carcinoma kinase 4 (CCK-4). Subsequent cancer research revealed that PTK7 also plays a crucial role in various other cancers, such as lung, breast, gastric, ovarian, colon, and rectal cancer, as well as other various malignancies.

PTK7 is now being evaluated as a potential target for cancer treatment because it is highly expressed in many solid tumors, including triple-negative breast cancer and ovarian cancer, while its distribution in normal adult tissues is more restricted. 

Its association with tumor-initiating cells, treatment resistance, tumor progression, and metastasis also supports continued development of therapeutic strategies targeting PTK7. Evidence in hematological cancers is less established and may vary by disease context, so expression-based confirmation remains important.

Structure and Function of PTK7

The PTK7 gene is located on the short arm of human chromosome 6 (6p21.1). Its protein structure consists of three components: an extracellular region featuring 7 immunoglobulin (Ig)-like domains, a transmembrane domain, and a receptor tyrosine kinase family homologous domain lacking catalytic activity.

This architecture makes PTK7 a membrane receptor found on the cell surface and accessible to antibodies, even though it cannot bind ATP and Mg2+ in the manner of an active kinase.

Due to this lack of catalytic activity, PTK7 is classified as a pseudokinase and is unable to bind ATP and Mg²⁺ Membrane-type 1 matrix metalloproteinase (MT1-MMP) serves as the primary sheddase for PTK7; it can directly cleave the exposed PKP(621)↓LI sequence on PTK7, producing a soluble PTK7 N-terminal fragment (sPTK7).

Schematic Diagram of PTK7 Protein Structure^[1]

Studies related to colon cancer demonstrate that PTK7 is first cleaved by ADAM17, generating a soluble fragment containing the 7 Ig-like domains (sPTK7-Ig1-7) and C-terminal fragment 1 (PTK7-CTF1). The generated PTK7-CTF1 is further cleaved by γ-secretase into PTK7 C-terminal fragment 2 (PTK7-CTF2). After translocating to the nucleus, PTK7-CTF2 promotes the proliferation and migration of the SW480 colon cancer cell line. These cleavage-dependent effects provide new insights into the molecular mechanisms through which PTK7 may influence cancer progression.  

Intracellular Domains Generated by PTK7 Cleavage Promote Colon Cancer Development^[1]

As a co-receptor of the Wnt signaling pathway, PTK7 is involved in regulating physiological processes such as cell proliferation, cell migration, the establishment of planar cell polarity, and differentiation under normal conditions, playing a critical role in tissue morphogenesis and tissue patterning.

Conversely, dysregulated tyrosine kinase 7 (PTK7) expression has been detected in primary tumors and experimental models of multiple cancers. Research indicates that in low-passage patient-derived xenograft (PDX) models of triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer, PTK7 is abundantly expressed on tumor-initiating cells (TICs), promotes tumor growth and invasion, and participates in mediating tumor therapeutic resistance, with its activity level directly correlating to poor cancer prognosis^[2][3].

These recent insights reinforce its therapeutic potential, although tumor type, expression density, internalization, and intratumoral heterogeneity can all affect response.

Different Roles of PTK7 in Physiological Conditions and Cancer Progression^[3]

PTK7-Mediated Signaling Pathways

The Wnt signaling pathway is a vital mediating pathway through which protein tyrosine kinase 7 regulates organismal functions; PTK7 can interact with various Wnt receptors, thereby influencing both canonical and non-canonical Wnt signaling pathways.

The exact role of PTK7 within the canonical Wnt signaling pathway remains controversial; some studies confirm that it activates this pathway, while others indicate it exerts an inhibitory effect. This context dependence warrants further investigation using complementary biochemical, genetic, and pharmacological modulation methods.

Additionally, PTK7 is involved in regulating the planar cell polarity (PCP) pathway, which determines the orientation of cells within an epithelial plane, a process reflecting PTK7's role in the non-canonical Wnt signaling pathway. PTK7's role as a molecular signaling switch is not limited to the Wnt pathway; it can also act as a molecular switch for the vascular endothelial growth factor (VEGF) signaling pathway and can form a receptor complex with Flt-1 (VEGFR1), playing a key role in Flt-1-mediated angiogenesis^[1]. 

PTK7-Mediated Canonical/Non-Canonical Wnt Signaling Pathways^[4]

Non-canonical Wnt/Planar Cell Polarity (PCP) Pathway

Non-canonical PCP signaling is activated by ligands such as Wnt5a and Wnt11. This signal is transduced via Frizzled receptors and Dishevelled (Dsh) proteins, activating the GTPases RhoA and Rac, as well as their respective effector molecules Rho-associated kinase (Rock) and c-Jun N-terminal kinase (JNK). In the presence of Frizzled, PTK7 can bind to Dsh and participate in the activation of the Wnt/PCP pathway; the abnormal activation of this pathway plays a significant role in driving cancer progression, invasive metastasis, and angiogenesis. 

Canonical Wnt Pathway 

In the absence of Wnt ligands, cytoplasmic β-catenin binds with adenomatous polyposis coli (APC) protein, Axin-1, and glycogen synthase kinase 3β (GSK3β) to form a "destruction complex," which continuously phosphorylates β-catenin, leading to its degradation via a ubiquitin-mediated pathway. Because β-catenin levels are kept low, it cannot enter the nucleus, and the canonical Wnt pathway remains in an "off" state. Upon stimulation by the Wnt3a ligand, this complex disintegrates in a Dsh-dependent manner. PTK7 can stabilize β-catenin at the membrane, allowing it to accumulate and translocate to the nucleus, where it binds with lymphoid enhancer-binding factor/T-cell factor (LEF/TCF) transcription factors to activate the expression of target genes, thereby exerting a positive regulatory effect. Whether PTK7 similarly interacts with Dsh in the canonical Wnt pathway, and whether it binds with other receptors, still requires further investigation. However, the role of PTK7 in the canonical Wnt pathway is heavily debated; functional experiments conducted by other researchers in Xenopus, Drosophila, and mammalian cells have demonstrated that PTK7 inhibits the canonical Wnt signaling underscoring the need for systems-level proteomics and pharmacological modulation studies[5]. 

PTK7 Drug Development Progress

Because PTK7 lacks catalytic activity, it is difficult to follow the conventional strategies used for receptor tyrosine kinases to develop small-molecule inhibitors. The principal modality is therefore the antibody-drug conjugate (ADC), which uses a PTK7-binding antibody to internalize and deliver a cytotoxic payload. This approach has been explored across advanced solid tumors, including lung, breast, gynecologic, and gastrointestinal tumor types.

Following the clinical failures of Cofetuzumab Pelidotin and PRO1107, the current PTK7-targeted drug market has formed a competitive landscape with Kelun-Biotech leading the way, while various domestic and international pharmaceutical companies are accelerating to break through.

SKB-518, developed by Kelun-Biotech based on its OptiDC™ platform, is a PTK7-directed antibody-drug conjugate. Its phase I clinical trial in patients with advanced solid tumors evaluates safety, tolerability, pharmacokinetics, and antitumor activity. As of August 2026, Kelun-Biotech also lists phase II studies in lung cancer and advanced gynecologic malignancies. 

These studies extend the program beyond its initial preclinical evaluation and help define dose, activity, and biomarker relationships in the clinical treatment setting.

The IND application for this drug targeting advanced solid tumor indications has been approved by the FDA and CDE, and it is currently in phase I clinical trials. MTX-13 is being jointly developed by MabCare and ProfoundBio; in June 2024, Day One announced an exclusive licensing agreement with MabCare for MTX-13, granting Day One exclusive global development, manufacturing, and commercialization rights outside of Greater China, and the drug is currently in phase I clinical trials. MTX-13 consists of an anti-PTK7 monoclonal antibody (Ab13) conjugated via a self-cleaving linker T1000 to 8 molecules of exatecan (a topoisomerase I inhibitor). In cell line-derived and patient-derived xenograft models of multiple solid tumors, MTX-13 demonstrated potent anti-tumor activity, with significantly superior efficacy compared to Cofetuzumab Pelidotin. In squamous cell carcinomas originating from different anatomical sites, MTX-13 exhibited potent anti-tumor activity. In rhesus monkeys, MTX-13 showed favorable pharmacokinetics and safety, with its highest non-severely toxic dose (HNSTD) ≥30 mg/kg, far exceeding the 3–5 mg/kg of Cofetuzumab Pelidotin. 

Structure and Pharmacological Advantages of MTX-13^[6] 

In addition to the above ADCs targeting a single PTK7 epitope, Zymeworks is developing a biparatopic ADC drug targeting two distinct PTK7 epitopes, specifically the Ig4 and Ig3-4 epitopes in the extracellular domain of PTK7; the two epitopes do not overlap, and the drug is currently in the preclinical stage. At the 2025 AACR Annual Meeting, Zymeworks disclosed relevant data showing that adopting a PTK7 biparatopic targeting strategy can significantly enhance antibody binding affinity and receptor-mediated endocytosis efficiency, achieving more efficient delivery of cytotoxic payloads to tumor cells. The drug demonstrated anti-tumor activity in both breast and lung cancer models, indicating a potential efficacy improvement over Cofetuzumab Pelidotin; furthermore, in non-human primate models, the drug still exhibited excellent safety and tolerability at a dose of 60 mg/kg. 

Recognition Sites of the Biparatopic PTK7 ADC Drug^[7]

A selection of PTK7 targeted drugs

KACTUS Supplies High-Quality PTK7 Proteins

As a key Wnt pathway co-receptor, PTK7 is a promising target in ADC and radiopharmaceutical development because it is highly expressed in multiple tumor settings and is associated with invasion, treatment resistance, and poor prognosis.

Despite clinical setbacks for drug candidates like Cofetuzumab Pelidotin, the immense potential of PTK7-targeted therapies continues to attract domestic and international pharmaceutical companies to accelerate their positioning.

KACTUS supplies high-quality wild-type PTK7 proteins, mutants, and PTK7 domain proteins, covering multiple species and featuring various tag designs.

These products have undergone strict quality control and are suitable for diverse application scenarios such as immunization, screening, and epitope identification, fully supporting the development of PTK7-targeted drugs. 

They can support hybridoma technology, engineering of a chimeric version, and early discovery for an antibody-drug conjugate (ADC) or targeted radionuclide therapy program.

Strict quality control helps researchers compare binding, internalization, and candidate performance before advancing into mouse studies or formal preclinical evaluation. For PTK7-targeted programs, KACTUS proteins can support target validation, selection of lead binders, and development of therapeutic methods targeting PTK7 across various malignancies.

Frequently Asked Questions

1. Why is PTK7 considered a promising target for cancer therapy?

PTK7 is accessible on the tumor-cell surface, is highly expressed in several solid tumors, and is associated with tumor growth, metastasis, drug resistance, and poor prognosis. It is particularly relevant to triple-negative breast cancer, ovarian cancer, lung cancer, and gastrointestinal indications such as rectal and colon cancer. These features give protein tyrosine kinase 7 substantial therapeutic potential, although expression and internalization should be confirmed for each tumor type and patient population.

2. Which PTK7 therapeutic modalities are currently being investigated?

The leading modality is the antibody-drug conjugate, including monospecific and biparatopic designs for advanced solid tumors. PTK7 is also being explored through targeted radionuclide therapy using an antibody-radionuclide conjugate. These complementary therapeutic strategies use PTK7-mediated targeting to deliver a cytotoxic or radioactive payload. Each format requires separate assessment of specific binding, internalization, pharmacokinetics, safety, and potential efficacy before it can become an established cancer treatment.

3. What preclinical evidence supports PTK7 targeting in ovarian cancer?

In the published OI-1 study, hybridoma technology generated a murine antibody and a human IgG1 chimeric version. A cell-based screening approach, flow cytometry, and surface plasmon resonance analyses verified the target and binding properties. Strong expression was observed in ovarian cancer tissues, and in vitro studies confirmed internalization in an SKOV-3-luc ovarian cancer cell line. In biodistribution studies, the radiolabeled antibody achieved high tumor uptake in xenograft mice. An intraperitoneal xenograft model of intraperitoneal ovarian cancer then showed significant tumor growth inhibition after intraperitoneal treatment, supporting therapeutic efficacy and additional in vivo efficacy studies.

4. What should buyers consider when choosing recombinant PTK7 proteins?

Buyers should match the construct to the intended assay, including species, tag, oligomeric state, extracellular-domain coverage, and individual Ig-like domains. Quality documentation should address identity, purity, homogeneity, and functional binding. For antibody discovery, recombinant proteins should be compatible with surface plasmon resonance analyses, immunization, epitope mapping, and a cell-based screening approach. 

5. How can KACTUS PTK7 proteins support preclinical drug development?

KACTUS PTK7 proteins can support antibody generation, affinity ranking, epitope identification, and specificity assessment for an antibody-drug conjugate (ADC) or antibody-radionuclide conjugate. They are relevant to preclinical evaluation in mice, selection of a suitable preclinical model, and planning studies that assess high tumor uptake, safety, and activity. These applications span cancer research, molecular medicine, radiation biology, and basic medical sciences, helping teams generate recent insights and select therapeutic strategies targeting tyrosine kinase 7 (PTK7) before entering a human clinical trial.

Product Data

Immobilized Human PTK7, His Tag at 0.5 μg/ml (100μl/well) on the plate. Dose response curve for Anti-PTK7 Antibody, hFc Tag with the EC50 of 2.0 ng/ml determined by ELISA (QC Test).

Immobilized Cynomolgus PTK7, His Tag at 0.5 μg/ml (100μl/well) on the plate. Dose response curve for Anti-PTK7 Antibody, hFc Tag with the EC50 of 3.3ng/ml determined by ELISA. (QC Test)

Related Product

References

[1] Jin Z, Guo T, Zhang X, Wang X, Liu Y. PTK7: an underestimated contributor to human cancer. Front Oncol. 2024 Oct 15;14:1448695. doi: 10.3389/fonc.2024.1448695. PMID: 39474113; PMCID: PMC11518688.
[2] Marc Damelin et al.A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.Sci. Transl. Med.9,eaag2611(2017).DOI:10.1126/scitranslmed.aag2611
[3] Mottard K, Cokaiko J, Rogister B, Neirinckx V. Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview. Oncologist. 2025 Aug 4;30(8):oyae290. doi: 10.1093/oncolo/oyae290. PMID: 39468753; PMCID: PMC12395136.
[4] Lhoumeau AC, Puppo F, Prébet T, Kodjabachian L, Borg JP. PTK7: a cell polarity receptor with multiple facets. Cell Cycle. 2011 Apr 15;10(8):1233-6. doi: 10.4161/cc.10.8.15368. Epub 2011 Apr 15. PMID: 21415598.
[5] Peradziryi H, Tolwinski NS, Borchers A. The many roles of PTK7: a versatile regulator of cell-cell communication. Arch Biochem Biophys. 2012 Aug 1;524(1):71-6. doi: 10.1016/j.abb.2011.12.019. Epub 2012 Jan 3. PMID: 22230326.
[6] Kong C, Pu J, Zhao Q, Weng W, Ma L, Qian Y, Hu W, Meng X, Meng T. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Mol Cancer Ther. 2023 Oct 2;22(10):1128-1143. doi: 10.1158/1535-7163.MCT-23-0164. PMID: 37352387; PMCID: PMC10544008.
[7] PTK7-BiP-ADC-2025-AACR-Poster_Final_April-14-1.pdf